Your browser doesn't support javascript.
loading
New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Moore, Donald C; Peery, Matthew R; Tobon, Katherine A; Raheem, Farah; Hwang, Grace S; Alhennawi, Lin; Hughes, Mitchell E.
  • Moore DC; Department of Pharmacy, Atrium Health, 536516Levine Cancer Institute, Concord, NC, United States.
  • Peery MR; Department of Pharmacy, 6887Virginia Commonwealth University Health, Richmond, VA, United States.
  • Tobon KA; Malignant Hematology Program, 25301Moffitt Cancer Center, Tampa, FL, United States.
  • Raheem F; 23387Mayo Clinic, Phoenix, AZ, United States.
  • Hwang GS; 24083Baylor St Luke's Medical Center, Houston, TX, United States.
  • Alhennawi L; 15502University of Cincinnati College of Pharmacy, Cincinnati, OH, United States.
  • Hughes ME; Lymphoma Program, Hematology/Oncology Division, Perelman Center for Advanced Medicine, 21798University of Pennsylvania, Philadelphia, PA, United States.
J Oncol Pharm Pract ; 28(8): 1848-1858, 2022 Dec.
Article en En | MEDLINE | ID: mdl-35469489
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Linfoma de Células B Grandes Difuso Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Linfoma de Células B Grandes Difuso Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article